Genmab/GMAB

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Genmab

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Ticker

GMAB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

Headquarters

Koebenhavn v, Denmark

Employees

2,286
Website
www.genmab.com

Genmab Metrics

BasicAdvanced
$19B
Market cap
23.41
P/E ratio
$1.20
EPS
0.98
Beta
-
Dividend rate
$19B
0.98
$42.72
$26.32
10
12.457
12.419
2.825
3.108
16.25%
18.27%
17.48%
23.413
7.201
3.886
3.939
23.872
16.71%
5.08%
17.67%
-2.94%

What the Analysts think about Genmab

Analyst Ratings

Majority rating from 10 analysts.
Buy

Genmab Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
31.98% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
kr 4.1B
-11.44%
Net income
kr 1.3B
107.03%
Profit margin
31.98%
133.77%

Genmab Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 110.00%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.30
$0.47
$0.14
$0.29
-
Expected
$2.18
$3.14
$3.26
$0.14
$0.33
Surprise
-86.20%
-84.96%
-95.70%
110.00%
-

Genmab News

AllArticlesVideos

Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma

Business Wire·5 days ago

Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma

GlobeNewsWire·5 days ago

Completion of Share Buy-back Program

GlobeNewsWire·6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractionalADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Genmab stock?

Genmab (GMAB) has a market cap of $19B as of July 03, 2024.

What is the P/E ratio for Genmab stock?

The price to earnings (P/E) ratio for Genmab (GMAB) stock is 23.41 as of July 03, 2024.

Does Genmab stock pay dividends?

No, Genmab (GMAB) stock does not pay dividends to its shareholders as of July 03, 2024.

When is the next Genmab dividend payment date?

Genmab (GMAB) stock does not pay dividends to its shareholders.

What is the beta indicator for Genmab?

Genmab (GMAB) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Genmab stock

Buy or sell Genmab stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing